Adhesion molecules: a new target for immunoliposome-mediated drug delivery.
The anti-ICAM-1 monoclonal antibody F10.2 was conjugated to liposomes to target to cells expressing the cell adhesion molecule ICAM-1. We demonstrate that F10.2 immunoliposomes bind to human bronchial epithelial cells (BEAS-2B) and human umbilical vein endothelial cells (HUVEC) in a specific, dose- and time-dependent manner. It appears that the degree of ICAM-1 expression is the limiting factor in the degree of immunoliposome binding to the cells. These results are a first step in the strategy for specific drug delivery to target sites characterised by increased expression of adhesion molecules.
Bloemen
P G
PG
Department of Pharmacology, Utrecht University, The Netherlands.
Henricks
P A
PA
van Bloois
L
L
van den Tweel
M C
MC
Bloem
A C
AC
Nijkamp
F P
FP
Crommelin
D J
DJ
Storm
G
G
D000911:Antibodies, Monoclonal / Q000276:immunology*; D001980:Bronchi / Q000166:cytology / Q000276:immunology; D002460:Cell Line; D016503:Drug Delivery Systems; D004730:Endothelium, Vascular / Q000166:cytology / Q000276:immunology; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000276:immunology*; D008081:Liposomes; D014471:Umbilical Veins
D000911:Antibodies, Monoclonal; D008081:Liposomes; D018799:Intercellular Adhesion Molecule-1